The drugmaker announced plans to discontinue a phase three trial for the shot in a March 29 press release, describing the decision as “part of a broader effort to make strategic choices for its pipeline and research and development investments to focus on medicines with the greatest potential benefit to patients.”
Johnson & Johnson first launched the phase three trial in September 2021, which involved about 23,000 adults aged 60 and older.
Meanwhile, several other drugmakers, including Pfizer, are pushing ahead with plans to gain FDA approval for their RSV vaccine candidates. There is currently no approved vaccine for the disease.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
